Aberdeen Smaller Companies Income Trust is an investment trust. Co. provides dividend and capital growth from a portfolio invested principally in the ordinary shares of smaller U.K. companies and U.K. fixed income securities. Co. invests in equities, corporate bonds and preference shares. Co. has appointed Aberdeen Fund Managers Limited (AFML) to act as the alternative investment fund manager. Co.'s portfolio is managed on a day-to-day basis by Aberdeen Asset Managers Limited (AAML) by way of a delegation agreement in place between AFML and AAML.

Astellas Pharma is engaged in the development, research, manufacture, and sale of pharmaceuticals. Co. operates its operation in Japan, Americas, Europe, and Asia/Oceania. Co.'s principal product for the global market include "Xtandi" a therapeutic agent for prostatic cancer, "Eligard" a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of prostate cancer,"Prograf" an immunosuppressant used to prevent rejection in organ transplants, "Vesicare" a treatment for overactive bladder, "Harnal ( "Omnic" in the U.S. and Europe)" an 1 blocking agent for prostatic and urethral smooth muscle, and "Fungurad ("Mycamine" in the U.S. and Europe)" a candin-type antifungal agent.

Daiichi Sankyo is engaged in the research and development, manufacture, sales, and marketing of pharmaceutical products. Co. operates its operation in Japan, the Americas, Europe, China and Asia. Co. provides ethical pharmaceutical and proprietary drugs. Co.'s principal products include antihypertensive agent "Olmetec" ("Olmesartan" in overseas), ulcer treatment drug "NEXIUM," Alzheimer's disease treatment "Memary," anti-influenza treatment "Inavir," antiplatelet agent "Prasugrel," anticoagulant "Edoxaban," anti-inflammatory analgesic "Loxonin" Tape, synthetic antibacterial agent "Cravit," treatment for bone complications "RANMARK," and anticoagulant "LIXIANA."

Shionogi is the parent company of a group engaged in the research and development, purchase, manufacture and sale of pharmaceutical products. Co.'s principal prescription drugs are "Crestor Tablet" for hyperlipidemia treatment, "Irbetan Tablet" for antihypertensive, "Cymbalta Capsule" for treatment for depression and depressive symptoms, "Finibax" and "Finibax Kit" for carbapenem antibiotic, "Differin Gel" for acne vulgaris treatment, "Pirespa Tablet" for idiopathic pulmonary fibrosis treatment, and "OxyContin Tablet" and "OxiNorm Powder" for cancer pain analgesic, and OTC drugs including "Sedes First," "Sedes Hi G," "Pylon," "Rapiacta Bag" and "Rapiacta Vial."

Ube Industries is engaged in the manufacture and sale of chemicals and cement products. Chemicals segment offers caprolactam, polyamide resins, polybutadiene, industrial chemicals, specialty products and fine chemicals. Pharmaceuticals segment offers active pharmaceutical ingredients and intermediates. Cement & Construction Materials segment offers cement, ready-mixed concrete, limestone and building materials. Machinery segment offers molding machines, industrial machinery and bridges and steel structures. Energy & Environment segment is engaged in the import and sales of coal and the supply of electric power. Co. is also engaged in the real estate business.